2x-121
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2018 (NCT03562832)
Timeline
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
- Poly [ADP-ribose] polymerase 2INHIBITOR
Poly [ADP-ribose] polymerase 2 inhibitor
- Poly [ADP-ribose] polymerase-1INHIBITOR
Poly [ADP-ribose] polymerase-1 inhibitor
- Tankyrase 1/2INHIBITOR
Tankyrase 1/2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]nc2c3c(cccc13)N=C(CN1Cc3ccccc3C1)N2- Mol. weight
- 317.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3644587 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05571969 | Phase 1 | Oct 20, 2022 | Allarity Therapeutics, Amarex Clinical Research |
| NCT03878849 | Phase 2 | Apr 15, 2019 | Alcedis GmbH, Amarex Clinical Research, Oncology Venture |
| NCT03562832 | Phase 2 | Jun 20, 2018 | Danish Breast Cancer Cooperative Group, Oncology Venture, Smerud Medical Research Denmark |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amarex Clinical Research | For profit | 2 | 0 | 2 | 2019 |
| Oncology Venture | For profit | 2 | 2 | 1 | 2018 |
| Alcedis GmbH | For profit | 1 | 0 | 1 | 2019 |
| Allarity Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Danish Breast Cancer Cooperative Group | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Smerud Medical Research Denmark | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1